These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 24131779)

  • 1. A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies.
    Nemunaitis JJ; Small KA; Kirschmeier P; Zhang D; Zhu Y; Jou YM; Statkevich P; Yao SL; Bannerji R
    J Transl Med; 2013 Oct; 11():259. PubMed ID: 24131779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.
    Mita MM; Mita AC; Moseley JL; Poon J; Small KA; Jou YM; Kirschmeier P; Zhang D; Zhu Y; Statkevich P; Sankhala KK; Sarantopoulos J; Cleary JM; Chirieac LR; Rodig SJ; Bannerji R; Shapiro GI
    Br J Cancer; 2017 Oct; 117(9):1258-1268. PubMed ID: 28859059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies.
    Zhang D; Mita M; Shapiro GI; Poon J; Small K; Tzontcheva A; Kantesaria B; Zhu Y; Bannerji R; Statkevich P
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):891-8. PubMed ID: 23053255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias.
    Gojo I; Sadowska M; Walker A; Feldman EJ; Iyer SP; Baer MR; Sausville EA; Lapidus RG; Zhang D; Zhu Y; Jou YM; Poon J; Small K; Bannerji R
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):897-908. PubMed ID: 23949430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients.
    Fabre C; Gobbi M; Ezzili C; Zoubir M; Sablin MP; Small K; Im E; Shinwari N; Zhang D; Zhou H; Le Tourneau C
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):1057-64. PubMed ID: 25217392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer.
    Mitri Z; Karakas C; Wei C; Briones B; Simmons H; Ibrahim N; Alvarez R; Murray JL; Keyomarsi K; Moulder S
    Invest New Drugs; 2015 Aug; 33(4):890-4. PubMed ID: 25947565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer.
    Mita MM; Joy AA; Mita A; Sankhala K; Jou YM; Zhang D; Statkevich P; Zhu Y; Yao SL; Small K; Bannerji R; Shapiro CL
    Clin Breast Cancer; 2014 Jun; 14(3):169-76. PubMed ID: 24393852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia.
    Flynn J; Jones J; Johnson AJ; Andritsos L; Maddocks K; Jaglowski S; Hessler J; Grever MR; Im E; Zhou H; Zhu Y; Zhang D; Small K; Bannerji R; Byrd JC
    Leukemia; 2015 Jul; 29(7):1524-9. PubMed ID: 25708835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.
    Kumar SK; LaPlant B; Chng WJ; Zonder J; Callander N; Fonseca R; Fruth B; Roy V; Erlichman C; Stewart AK;
    Blood; 2015 Jan; 125(3):443-8. PubMed ID: 25395429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.
    Dolly SO; Wagner AJ; Bendell JC; Kindler HL; Krug LM; Seiwert TY; Zauderer MG; Lolkema MP; Apt D; Yeh RF; Fredrickson JO; Spoerke JM; Koeppen H; Ware JA; Lauchle JO; Burris HA; de Bono JS
    Clin Cancer Res; 2016 Jun; 22(12):2874-84. PubMed ID: 26787751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors.
    Massard C; Soria JC; Anthoney DA; Proctor A; Scaburri A; Pacciarini MA; Laffranchi B; Pellizzoni C; Kroemer G; Armand JP; Balheda R; Twelves CJ
    Cell Cycle; 2011 Mar; 10(6):963-70. PubMed ID: 21368575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.
    Gorlick R; Kolb EA; Houghton PJ; Morton CL; Neale G; Keir ST; Carol H; Lock R; Phelps D; Kang MH; Reynolds CP; Maris JM; Billups C; Smith MA
    Pediatr Blood Cancer; 2012 Dec; 59(7):1266-74. PubMed ID: 22315240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dinaciclib for the treatment of breast cancer.
    Criscitiello C; Viale G; Esposito A; Curigliano G
    Expert Opin Investig Drugs; 2014 Sep; 23(9):1305-12. PubMed ID: 25107301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer.
    Stephenson JJ; Nemunaitis J; Joy AA; Martin JC; Jou YM; Zhang D; Statkevich P; Yao SL; Zhu Y; Zhou H; Small K; Bannerji R; Edelman MJ
    Lung Cancer; 2014 Feb; 83(2):219-23. PubMed ID: 24388167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia.
    Chen Y; Germano S; Clements C; Samuel J; Shelmani G; Jayne S; Dyer MJ; Macip S
    Br J Haematol; 2016 Nov; 175(4):641-651. PubMed ID: 27469405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.
    Parry D; Guzi T; Shanahan F; Davis N; Prabhavalkar D; Wiswell D; Seghezzi W; Paruch K; Dwyer MP; Doll R; Nomeir A; Windsor W; Fischmann T; Wang Y; Oft M; Chen T; Kirschmeier P; Lees EM
    Mol Cancer Ther; 2010 Aug; 9(8):2344-53. PubMed ID: 20663931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer.
    Lin SF; Lin JD; Hsueh C; Chou TC; Wong RJ
    PLoS One; 2017; 12(2):e0172315. PubMed ID: 28207834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.
    Papadopoulos KP; Ben-Ami E; Patnaik A; Trone D; Li J; Demetri GD
    BMC Cancer; 2018 Aug; 18(1):790. PubMed ID: 30081867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.
    Boss DS; Schwartz GK; Middleton MR; Amakye DD; Swaisland H; Midgley RS; Ranson M; Danson S; Calvert H; Plummer R; Morris C; Carvajal RD; Chirieac LR; Schellens JHM; Shapiro GI
    Ann Oncol; 2010 Apr; 21(4):884-894. PubMed ID: 19825886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors.
    Mahadevan D; Plummer R; Squires MS; Rensvold D; Kurtin S; Pretzinger C; Dragovich T; Adams J; Lock V; Smith DM; Von Hoff D; Calvert H
    Ann Oncol; 2011 Sep; 22(9):2137-2143. PubMed ID: 21325451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.